EP2162743A4 - Methods of modulating inflammation and compositions therefore - Google Patents

Methods of modulating inflammation and compositions therefore

Info

Publication number
EP2162743A4
EP2162743A4 EP08767898A EP08767898A EP2162743A4 EP 2162743 A4 EP2162743 A4 EP 2162743A4 EP 08767898 A EP08767898 A EP 08767898A EP 08767898 A EP08767898 A EP 08767898A EP 2162743 A4 EP2162743 A4 EP 2162743A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
modulating inflammation
inflammation
modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08767898A
Other languages
German (de)
French (fr)
Other versions
EP2162743A2 (en
Inventor
Fred Finkelman
Marat Khodoun
Marsha Willis-Karp
Christina Lewis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Cincinnati
Original Assignee
University of Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Cincinnati filed Critical University of Cincinnati
Publication of EP2162743A2 publication Critical patent/EP2162743A2/en
Publication of EP2162743A4 publication Critical patent/EP2162743A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5437—IL-13
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
EP08767898A 2007-05-29 2008-05-28 Methods of modulating inflammation and compositions therefore Withdrawn EP2162743A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93209507P 2007-05-29 2007-05-29
PCT/US2008/006728 WO2008153790A2 (en) 2007-05-29 2008-05-28 Methods of modulating inflammation and compositions therefore

Publications (2)

Publication Number Publication Date
EP2162743A2 EP2162743A2 (en) 2010-03-17
EP2162743A4 true EP2162743A4 (en) 2010-07-14

Family

ID=40130387

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08767898A Withdrawn EP2162743A4 (en) 2007-05-29 2008-05-28 Methods of modulating inflammation and compositions therefore

Country Status (3)

Country Link
EP (1) EP2162743A4 (en)
CA (1) CA2688256A1 (en)
WO (1) WO2008153790A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2948770B1 (en) * 2013-01-23 2020-11-18 Institut National de la Santé et de la Recherche Médicale Number of il4 and/or il3 secreting t-cells as a biomarker for allergic diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000036103A1 (en) * 1998-12-14 2000-06-22 Genetics Institute, Inc. Cytokine receptor chain
US20040247524A1 (en) * 2003-06-05 2004-12-09 Philippe Naquet Method of treatment of an inflammatory disorder with a Vanin-1 antagonist
JP2005095166A (en) * 2003-08-28 2005-04-14 Sumitomo Pharmaceut Co Ltd Disease marker of inflammatory bowel disease and utilization of the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE540695T1 (en) * 2001-06-08 2012-01-15 Genaera Corp METHOD FOR MODULATING IL-13
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000036103A1 (en) * 1998-12-14 2000-06-22 Genetics Institute, Inc. Cytokine receptor chain
US20040247524A1 (en) * 2003-06-05 2004-12-09 Philippe Naquet Method of treatment of an inflammatory disorder with a Vanin-1 antagonist
JP2005095166A (en) * 2003-08-28 2005-04-14 Sumitomo Pharmaceut Co Ltd Disease marker of inflammatory bowel disease and utilization of the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 13 December 2002 (2002-12-13), "Mus musculus adult male stomach cDNA, RIKEN full-length enriched library, clone:2210421G13 product:hypothetical protein, full insert sequence.", XP002583464, retrieved from EBI accession no. EMBL:AK075855 Database accession no. AK075855 *
KHODOUN MARAT ET AL: "Differences in expression, affinity, and function of soluble (s)IL-4R alpha and sIL-13R alpha 2 suggest opposite effects on allergic responses", JOURNAL OF IMMUNOLOGY, vol. 179, no. 10, November 2007 (2007-11-01), pages 6429 - 6438, XP002583463, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
CA2688256A1 (en) 2008-12-18
WO2008153790A2 (en) 2008-12-18
EP2162743A2 (en) 2010-03-17
WO2008153790A3 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
HRP20160902T1 (en) Compositions and methods of use of phorbolesters
HK1172326A1 (en) Compounds and compositions and methods of use
HK1161272A1 (en) Methods and compositions for specific modulation of mcl-1 mcl-1
EP2334185A4 (en) Compositions and methods of using (r)-pramipexole
EP2214707A4 (en) Compositions and methods for treating inflammation
EP2249791A4 (en) Compositions and devices
IL200576A0 (en) Inhibitors of rtp801 and their uses
HK1166305A1 (en) Compositions and methods for the treatment of inflammation
EP2231665A4 (en) Novel compositions and methods of use
PL2194783T3 (en) Compositions and methods for apoptosis modulators
EP2129680A4 (en) Combined hairpin-antisense compositions and methods for modulating expression
EP2349305A4 (en) Phytochemical compositions and methods for activating amp-kinase
EP2370815A4 (en) Anti-inflammatory compositions and methods
EP2134352A4 (en) Wnt compositions and methods of use thereof
TWI367763B (en) Compositions and devices
GB0812890D0 (en) Compositions and methods of making compositions
HK1151438A1 (en) Gas-effusing compositions and methods of making and using same
ZA201102207B (en) Cinnamandehyde-allicin compositions and their method of use
IL207827A0 (en) Apoaequorin-containing compositions and methods of using same
ZA201004894B (en) Nuctraceutical composition and methods of use
EP2300044A4 (en) Methods and compositions for the management of pain using omega-conotoxins
EP2162743A4 (en) Methods of modulating inflammation and compositions therefore
ZA201004893B (en) Nuctraceutical composition and methods of use
WO2009120815A9 (en) Therapeutic compositions and methods
AU2007906771A0 (en) Nutraceutical composition and methods of use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20091221

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

A4 Supplementary search report drawn up and despatched

Effective date: 20100610

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1142403

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110512

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1142403

Country of ref document: HK